Novozymes A/S

Novozymes A/S is a globally dominant biotech company headquartered in Copenhagen, Denmark, operating as a publicly listed entity on NASDAQ Copenhagen. As the world's undisputed leader in enzyme and microbial technology, the company serves industrial, agricultural, food, and household care sectors across more than 130 countries with a workforce of approximately 6,500 employees and annual revenue reaching roughly 150 billion Danish Kroner (approximately $2.2 billion USD).

Core Business

Novozymes operates as an end-to-end biomanufacturing company encompassing research, production, application, and sales. Its enzyme products constitute the absolute core of its portfolio, covering industrial enzymes, food-grade enzymes, and specialty enzymes supported by world-leading biocatalysis capabilities. The company maintains a robust microbial technology division, developing and supplying probiotic and microbiome-based solutions that address health and nutrition applications. In the realm of fermentation technology, Novozymes combines traditional and modern fermentation processes to deliver customized biological solutions for the food, beverage, and industrial sectors. Beyond these pillars, the company produces functional biological ingredients, biopolymers used as thickeners and stabilizers, and natural bio-preservation agents including antioxidant solutions that extend product shelf life sustainably.

Global Presence

Novozymes maintains an extensive global footprint spanning 130+ countries across four major regions. Europe serves as the core market, contributing 35% of revenue with operations across 30 countries including Denmark, Germany, France, and the United Kingdom. North America accounts for 30% of revenue across the United States, Canada, and Mexico, while the Asia-Pacific region represents a high-growth segment contributing 25% of revenue across 25 countries led by China, Japan, and India. Remaining regions, including Latin America, Africa, and the Middle East, contribute 10% of revenue as rapidly emerging markets. The company's operational infrastructure includes 9 production facilities strategically distributed in Denmark, the United States, China, and Brazil, with an annual bioproduct capacity exceeding 300,000 metric tons, alongside 6 dedicated fermentation plants, 7 global R&D centers staffed by 1,300 researchers, and 15 customer application laboratories worldwide.

Key Strengths

Novozymes distinguishes itself through an unrivaled technology portfolio comprising 4,000+ granted patents and a sustained R&D investment representing 13-14% of annual revenue, yielding over 100 new product launches and 50+ technological breakthroughs each year. The company commands an exceptional 48% global market share in the enzyme industry while operating under pharmaceutical-grade quality standards including strict cGMP compliance and full traceability systems. Its sustainability impact is substantial, having helped customers avoid 80 million metric tons of carbon emissions and conserve 30 billion cubic meters of water annually. The company also leads in green manufacturing, having reduced its own carbon emission intensity by 25%, improved water efficiency by 30%, and achieved a 90% waste valorization rate across its global operations.